Vistagen (VTGN) Stock Plummets 80% After Phase 3 Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Globenewswire
- Lawsuit Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Vistagen on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, to apply as lead plaintiffs.
- False Statements Allegation: The complaint alleges that Vistagen misled investors with overwhelmingly positive statements while concealing adverse facts regarding its Phase 3 PALISADE-3 trial for fasedienol, leading to significant investor losses.
- Stock Price Crash: Following the announcement on December 17, 2025, that the PALISADE-3 trial failed to meet its primary endpoint, Vistagen's stock plummeted from $4.36 per share to $0.86, representing an over 80% decline, severely impacting investor confidence.
- Legal Consultation Opportunity: Affected investors are encouraged to contact Bragar Eagel & Squire for legal rights and potential claims, with the firm offering consultations at no cost or obligation to assist investors in protecting their interests.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 0.97 USD with a low forecast of 0.90 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.634
Low
0.90
Averages
0.97
High
1.00
Current: 0.634
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
